Zura Bio (NASDAQ:ZURA) Cut to “Sell” at Wall Street Zen

Wall Street Zen downgraded shares of Zura Bio (NASDAQ:ZURA) from a hold rating to a sell rating in a report released on Sunday.

Several other equities analysts have also weighed in on ZURA. HC Wainwright decreased their target price on shares of Zura Bio from $3.00 to $2.00 and set a “neutral” rating on the stock in a report on Tuesday, August 19th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Zura Bio in a report on Tuesday, October 14th. Oppenheimer cut their target price on Zura Bio from $17.00 to $16.00 and set an “outperform” rating for the company in a research note on Friday, August 15th. Finally, Chardan Capital restated a “buy” rating and issued a $10.00 target price on shares of Zura Bio in a research report on Friday, November 14th. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Zura Bio has an average rating of “Moderate Buy” and an average target price of $10.75.

Zura Bio Stock Down 4.0%

Shares of NASDAQ:ZURA opened at $3.83 on Friday. Zura Bio has a 52-week low of $0.97 and a 52-week high of $4.68. The stock has a market cap of $249.03 million, a P/E ratio of -5.89 and a beta of 0.24. The business has a fifty day moving average of $3.37 and a two-hundred day moving average of $2.11.

Zura Bio (NASDAQ:ZURA) last posted its quarterly earnings results on Thursday, November 13th. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.02). On average, equities analysts anticipate that Zura Bio will post -0.65 earnings per share for the current year.

Institutional Investors Weigh In On Zura Bio

Several institutional investors and hedge funds have recently modified their holdings of the company. Savant Capital LLC boosted its holdings in Zura Bio by 190.4% during the 2nd quarter. Savant Capital LLC now owns 32,409 shares of the company’s stock valued at $34,000 after acquiring an additional 21,249 shares during the period. Scientech Research LLC acquired a new stake in shares of Zura Bio during the third quarter worth about $45,000. AQR Capital Management LLC purchased a new position in shares of Zura Bio in the first quarter valued at approximately $72,000. Nuveen LLC acquired a new position in shares of Zura Bio in the first quarter valued at approximately $76,000. Finally, Forefront Wealth Partners LLC purchased a new stake in Zura Bio during the 3rd quarter worth approximately $93,000. Hedge funds and other institutional investors own 61.14% of the company’s stock.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.